<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-05-30">30 May 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Oliver</forename><forename type="middle">A</forename><surname>Cornely</surname></persName>
							<email>oliver.cornely@uk-koeln.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department I of Internal Medicine</orgName>
								<orgName type="department" key="dep2">Center for Integrated Oncology (CIO Ko ¨lnBonn)</orgName>
								<orgName type="department" key="dep3">part-ner site Bonn-Cologne</orgName>
								<orgName type="laboratory" key="lab1">Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD)</orgName>
								<orgName type="laboratory" key="lab2">German Centre for Infection Research (DZIF)</orgName>
								<orgName type="institution" key="instit1">Clinical Trials Centre Cologne (ZKS)</orgName>
								<orgName type="institution" key="instit2">University of Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="department" key="dep1">Corresponding author</orgName>
								<orgName type="department" key="dep2">Department I for Internal Medicine</orgName>
								<orgName type="institution">University Hospital of Cologne</orgName>
								<address>
									<addrLine>Kerpener Straße 62</addrLine>
									<postCode>50937</postCode>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Thibaut</forename><surname>Leguay</surname></persName>
							<affiliation key="aff1">
								<orgName type="laboratory">Service d&apos;he ´matologie clinique et The ´rapie cellulaire</orgName>
								<orgName type="institution" key="instit1">Ho ˆpital du Haut-Le ´ve `que</orgName>
								<orgName type="institution" key="instit2">CHU de Bordeaux</orgName>
								<address>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johan</forename><surname>Maertens</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Microbiology and Immunology</orgName>
								<orgName type="department" key="dep2">Department of Hematology</orgName>
								<orgName type="institution" key="instit1">KU Leuven-University of Leuven</orgName>
								<orgName type="institution" key="instit2">University Hospitals Leuven</orgName>
								<address>
									<postCode>B-3000</postCode>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maria</forename><forename type="middle">J G T</forename><surname>Vehreschild</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department I of Internal Medicine</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Achilles</forename><surname>Anagnostopoulos</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Haematology Department -BMT Unit</orgName>
								<orgName type="institution">George Papanicolaou Hospital</orgName>
								<address>
									<postCode>57010</postCode>
									<settlement>Thessaloniki</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carlo</forename><surname>Castagnola</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Hematology Oncology</orgName>
								<orgName type="institution">Fondazione IRCCS Policlinico S. Matteo</orgName>
								<address>
									<settlement>Pavia</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Luisa</forename><surname>Verga</surname></persName>
							<affiliation key="aff6">
								<orgName type="institution">Ospedale San Gerardo</orgName>
								<address>
									<settlement>Monza</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christina</forename><surname>Rieger</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Medizinische Klinik und Poliklinik III</orgName>
								<orgName type="department" key="dep2">Klinikum</orgName>
								<orgName type="institution">Universit€ at Mu ¨nchen</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mustafa</forename><surname>Kondakci</surname></persName>
							<affiliation key="aff8">
								<orgName type="institution" key="instit1">Klinik fu ¨r H€ amatologie</orgName>
								<orgName type="institution" key="instit2">Onkologie und klin. Immunologie</orgName>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="institution">Universit€ atsklinikum Du ¨sseldorf</orgName>
								<address>
									<addrLine>Du ¨sseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Georg</forename><surname>H€ Arter</surname></persName>
							<affiliation key="aff10">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution" key="instit1">Zentrum fu ¨r Hormon-und Stoffwechselerkrankungen und Infektiologie</orgName>
								<orgName type="institution" key="instit2">MVZ Endokrinologikum Ulm</orgName>
								<orgName type="institution" key="instit3">Ulm University Hospital Medical Center</orgName>
								<address>
									<settlement>Ulm</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rafael</forename><forename type="middle">F</forename><surname>Duarte</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Hematology</orgName>
								<orgName type="institution">Hospital Universitario Puerta de Hierro Majadahonda</orgName>
								<address>
									<postCode>28222</postCode>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bernardino</forename><surname>Allione</surname></persName>
							<affiliation key="aff12">
								<orgName type="institution">Ospedale S. Giovanni Battista Molinette</orgName>
								<address>
									<settlement>Hematology, Torino</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Catherine</forename><surname>Cordonnier</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Hematology Department</orgName>
								<orgName type="institution" key="instit1">AP-HP-Henri Mondor</orgName>
								<orgName type="institution" key="instit2">University</orgName>
								<address>
									<addrLine>Paris-Est Creteil</addrLine>
									<postCode>F-94010</postCode>
									<settlement>Cre ´teil</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claus</forename><forename type="middle">Peter</forename><surname>Heussel</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution">Universit€ atsklinikum Heidelberg</orgName>
								<address>
									<settlement>Thoraxklinik, Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><forename type="middle">Orla</forename><surname>Morrissey</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Infectious Diseases</orgName>
								<orgName type="institution">Alfred Health and Monash University</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Samir</forename><forename type="middle">G</forename><surname>Agrawal</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Division of Haemato-Oncology</orgName>
								<orgName type="institution" key="instit1">St Bartholomew&apos;s Hospital</orgName>
								<orgName type="institution" key="instit2">Barts Cancer Institute</orgName>
								<orgName type="institution" key="instit3">Queen Mary University</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">Peter</forename><surname>Donnelly</surname></persName>
							<affiliation key="aff17">
								<orgName type="department" key="dep1">Department of Haematology</orgName>
								<orgName type="department" key="dep2">18 Gilead Sciences</orgName>
								<orgName type="institution">Radboud UMC</orgName>
								<address>
									<settlement>Nijmegen, Foster City</settlement>
									<region>CA</region>
									<country>the Netherlands;, USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mark</forename><surname>Bresnik</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><forename type="middle">J</forename><surname>Hawkins</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Will</forename><surname>Garner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Nicola</forename><surname>Go</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Medicine II</orgName>
								<orgName type="institution" key="instit1">University Hospital</orgName>
								<orgName type="institution" key="instit2">Goethe University</orgName>
								<address>
									<settlement>Frankfurt</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-05-30">30 May 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">D5F9601BB9392FC26DB93BF6F714C49D</idno>
					<idno type="DOI">10.1093/jac/dkx133</idno>
					<note type="submission">Received 21 December 2016; returned 17 February 2017; revised 4 April 2017; accepted 7 April 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:20+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objectives: To prevent invasive fungal disease (IFD) in adult patients undergoing remission-induction chemotherapy for newly diagnosed acute lymphoblastic leukaemia (ALL).</s></p><p><s>Patients and methods: In a double-blind multicentre Phase 3 study, patients received prophylactic liposomal amphotericin B (L-AMB) at 5 mg/kg intravenously or placebo twice weekly in a 2:1 random allocation during remission-induction treatment.</s><s>The primary endpoint was the development of proven or probable IFD.</s><s>Secondary endpoints included those focused on the safety and tolerability of prophylactic L-AMB.</s></p><p><s>Results: Three hundred and fifty-five patients from 86 centres in Europe and South America received at least one dose of L-AMB (n " 237) or placebo (n " 118).</s><s>Rates of proven and probable IFD assessed independently were 7.9% (18/228) in the L-AMB group and 11.7% (13/111) in the placebo group (P " 0.24).</s><s>Rates of possible IFD were 4.8% (11/228) in the L-AMB and 5.4% (6/111) in the placebo group (P " 0.82).</s><s>The remission-induction phase was a median of 22 days for both groups.</s><s>Overall mortality was similar between the groups: 7.2% (17/237) for L-AMB and 6.8% (8/118) for placebo (P " 1.00).</s><s>Hypokalaemia and creatinine increase were significantly more frequent with L-AMB.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions:</head><p><s>The IFD rate among adult patients undergoing remission-induction chemotherapy for newly diagnosed ALL was 11.7% in the placebo group, and was not significantly different in patients receiving L-AMB, suggesting that the L-AMB regimen studied is not effective as prophylaxis against IFD.</s><s>The IFD rate appears higher than previously reported, warranting further investigation.</s><s>Tolerability of L-AMB was what might be expected.</s><s>Further studies are needed to determine the optimal antifungal strategy during remission-induction chemotherapy of ALL.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Adult patients with acute lymphoblastic leukaemia (ALL) are given intensive multidrug chemotherapy to induce remission based on paediatric protocols of 6-8 weeks duration. <ref type="bibr" target="#b77">1</ref></s><s>During this period, patients are at risk of invasive fungal disease (IFD) due to neutropenia and exposure to high-dose glucocorticosteroids. <ref type="bibr" target="#b77">[1]</ref><ref type="bibr" target="#b78">[2]</ref><ref type="bibr" target="#b79">[3]</ref> IFD is challenging to diagnose, particularly in the early stages, when symptoms and signs are absent or non-specific. <ref type="bibr" target="#b80">4</ref></s><s>Moreover, IFD has considerable impact on morbidity and mortality, and may interrupt or delay chemotherapy, consequently reducing dose intensity and complete and molecular remission rates. <ref type="bibr" target="#b77">1,</ref><ref type="bibr" target="#b78">2</ref></s><s>Antifungal prophylaxis could potentially contribute to treatment efficacy. <ref type="bibr" target="#b81">5,</ref><ref type="bibr" target="#b82">6</ref></s><s>n IFD rate of 6.5% has been reported in a retrospective analysis of adult ALL patients, with aspergillosis and candidiasis predominating. <ref type="bibr" target="#b78">2</ref> An IFD rate of 8.8% has been reported in ALL patients with neutropenia, <ref type="bibr" target="#b83">7</ref> and a rate of 6.7% has been identified in patients receiving induction chemotherapy for the treatment of ALL. <ref type="bibr" target="#b84">8</ref> While prophylaxis with azole antifungals has been developed for other patient groups at similar risk, there is currently no approved standard of care for patients with ALL.</s><s><ref type="bibr" target="#b85">9,</ref><ref type="bibr" target="#b86">10</ref> The European Working Group for Adult ALL (EWALL) recommends that azole antifungals should be avoided because of drug-drug interactions with vinca alkaloids, a key component of ALL chemotherapy regimens.</s><s><ref type="bibr" target="#b77">1</ref> Liposomal amphotericin B (L-AMB) offers an alternative as it is active against a broad variety of fungi, including Aspergillus species, Candida species and agents of mucormycosis.</s><s><ref type="bibr" target="#b82">6,</ref><ref type="bibr" target="#b87">[11]</ref><ref type="bibr" target="#b89">[12]</ref><ref type="bibr" target="#b90">[13]</ref> Support for L-AMB use in treatment comes from studies examining its pharmacokinetics in animal models, healthy volunteers and neutropenic patients at doses between 1 and 7.5 mg/kg/day and knowledge that it has a long terminal elimination half-life.</s><s>7]<ref type="bibr" target="#b95">[18]</ref><ref type="bibr" target="#b96">[19]</ref><ref type="bibr" target="#b97">[20]</ref><ref type="bibr" target="#b98">[21]</ref> However, doses .5 mg/kg were associated with an increased incidence of infusion-related reactions.</s><s><ref type="bibr" target="#b95">18</ref> The medical need for antifungal prophylaxis was identified in close collaboration with EWALL.</s><s>The AmBiGuard study was designed to determine the efficacy and safety of L-AMB given at 5 mg/kg twice weekly compared with placebo to prevent IFD in adults undergoing remission-induction chemotherapy for newly diagnosed ALL.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and methods</head><p><s>The study was conducted at 86 centres in 13 countries in Europe and South America and registered on clinicaltrials.gov</s><s>(NCT01259713) and EudraCT  (2010-019562-91).</s><s>The study was conducted in accordance with the Declaration of Helsinki.</s><s>The protocol was approved by the institutional review board of each participating site.</s><s>Written informed consent was obtained from each patient.</s><s>An independent data safety monitoring board (DSMB) supervised the study and undertook a planned interim data review for futility when half the subjects had completed the study.</s><s>An independent data review board (IDRB) performed a blinded review of data from all patients to assess the presence of IFD according to the revised consensus definitions. <ref type="bibr" target="#b80">4</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Eligibility criteria</head><p><s>Adults 18 years were eligible provided they were to receive remissioninduction chemotherapy for newly diagnosed ALL that was likely to induce 10 days of neutropenia (absolute neutrophil counts ,500/lL), and were able to start the study drug within 5 days of the first dose of chemotherapy.</s><s>Patients were excluded if there was clinical suspicion of IFD including unexplained fever, evidence of pulmonary infiltrates on imaging or if they had been given antifungal treatment in the previous 30 days.</s><s>Patients were also excluded if their serum creatinine was .2</s><s>times the upper limit of normal (ULN), liver function tests were .5 % ULN <ref type="bibr" target="#b99">22</ref> or if there was any severe comorbidity or any hypersensitivity to amphotericin B.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study drug</head><p><s>The colour and overall appearance of L-AMB and placebo (riboflavin 5 0 phosphate formulated in soy phosphatidylcholine as liposomes) did not differ.</s><s>The two drugs were prepared and given in the same manner.</s><s>Study personnel were blinded to treatment allocation.</s><s>A blinded member of the pharmacy staff prepared the solutions and provided blind-labelled infusion bags for administration.</s><s>L-AMB was given at a dose of 5 mg/kg based on the patient's weight at screening and dose adjustment to weight changes was allowed.</s><s>This dose was selected in order to minimize toxicity.</s><s>Study drug was infused over 2 h twice weekly (3-4 day interval) during the entire remission-induction phase of chemotherapy.</s><s>The dosing schedule was chosen on practical grounds.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IFD monitoring and diagnostic-driven antifungal treatment</head><p><s>Patients underwent prospective monitoring for the development of IFD according to defined study algorithms throughout the duration of the study and for the 30 days after stopping the study drug (Figures <ref type="figure" target="#fig_0">S1-S3</ref>, available as Supplementary data at JAC Online).</s><s>Serum samples were drawn twice weekly and tested for galactomannan (GM) and 1,3-b-D-glucan (BDG) centrally in Belgium, Argentina or Brazil.</s><s>The results were reported to the site within 48-72 h.</s><s>A thoracic CT scan was recommended when the mycological criteria were met for a proven or probable IFD, and the study algorithm was followed according to the result (Figure <ref type="figure" target="#fig_1">S2</ref>). <ref type="bibr" target="#b100">23</ref></s><s>When no mycological criteria were met, 4 a work-up was undertaken when patients had unexplained fever (temperature 38 C for 72 h) despite antibiotic treatment, relapsing fever, new pulmonary infiltrates on chest X-ray or other potential signs and symptoms of IFD (Figure <ref type="figure">S3</ref>).</s></p><p><s>Systemically active antifungal agents were not permitted except for patients who developed oropharyngeal candidiasis despite topical measures; they were allowed to receive concomitant oral fluconazole at 100-200 mg for 10 days.</s></p><p><s>Study treatment was replaced for up to 5 days with an antifungal other than amphotericin B when there were findings suggestive of IFD to allow further diagnostic tests to be done.</s><s>Treatment was stopped and prophylaxis restarted when these tests proved negative.</s><s>Protocol-specified criteria to stop prophylaxis and start broad-spectrum antifungals were defined.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study procedures</head><p><s>All concomitant medications, including chemotherapy and other antimicrobials, were recorded from 30 days before recruitment and until study completion.</s><s>All adverse events (AEs) were recorded up to 30 days from last dose, regardless of their potential relationship to the study drug.</s><s>Laboratory assessments (haematology and chemistry) and complete or symptomdirected physical examinations, including vital signs and temperature, were done at scheduled times.</s></p><p><s>Study treatment ended for the patient when one of the following occurred: (i) diagnosis of a proven or probable IFD; (ii) remission-induction chemotherapy was completed, neutropenia resolved and the patient was well enough to be discharged from hospital; or (iii) consolidation or salvage chemotherapy was started.</s></p><p><s>Cornely et al.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacokinetic sampling</head><p><s>Amphotericin B serum trough concentrations were determined in a subset of patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy and safety endpoints</head><p><s>The primary efficacy endpoint was the development of proven or probable IFD during remission-induction chemotherapy, measured as the proportion of patients who met this endpoint as assessed by the IDRB.</s><s>Secondary endpoints included: the proportion in complete remission at last follow-up (e.g. 30 days after end of study treatment); the time to diagnosis of proven or probable IFD; the proportion that required antifungal treatment according to protocol guidance; the proportion of patients who developed pulmonary infiltrates; the proportion of patients with proven IFD and probable IFD; <ref type="bibr" target="#b80">4</ref> and the number of deaths due to IFD as assessed by the IDRB.</s><s>Additionally, the development of AEs and abnormal clinical laboratory results were examined.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Randomization, sample size and statistical methods</head><p><s>Patients who met the eligibility criteria were randomized, using an interactive voice or web response system, to receive either 5 mg/kg L-AMB or matched placebo twice weekly.</s><s>Randomization was done centrally and stratified by geographical region: Europe versus South America using permuted blocks (Table <ref type="table" target="#tab_0">S1</ref>).</s></p><p><s>The intended sample size (n " 354) was based on having 81% power to detect a 75% relative reduction in IFD in the L-AMB group, assuming a rate of IFD of 10% in the placebo group using a Cochran-Mantel-Haenszel (CMH) test with a 0.05 two-sided significance level and 2:1 allocation.</s><s>The assumed IFD rate of 10% for the placebo group is in line with previously reported prophylaxis studies in other patient populations at high risk of IFD. <ref type="bibr" target="#b86">10,</ref><ref type="bibr" target="#b101">24,</ref><ref type="bibr" target="#b102">25</ref></s><s>A 0.05 two-sided test was chosen because the interim boundaries were based around a two-sided test.</s><s>We selected 2:1 randomization of L-AMB to placebo rather than 1:1 randomization due to ethical considerations and its potential to provide more comprehensive safety data for the L-AMB group.</s></p><p><s>The primary efficacy analysis used the ITT population, i.e. all subjects who were randomly allocated to study treatment, who received at least one dose of study drug and met the major eligibility criteria (newly diagnosed with ALL and had not received systemically active antifungals within the previous 30 days).</s><s>An ITT analysis excluding patients who were never neutropenic was done as was a post hoc per-protocol analysis set excluding patients receiving antifungals not permitted by the protocol.</s><s>The safety analysis population included all patients who received at least one dose of the randomly allocated study drug.</s></p><p><s>All statistical tests were performed at the 0.05 level (unless otherwise stated) without consideration for multiplicity.</s><s>The CMH test was used for the primary analysis after adjusting for region.</s></p><p><s>A planned interim analysis for futility was undertaken when 50% of patients had completed the study, so a for the primary analysis was adjusted by 0.0003.</s></p><p><s>Categorical secondary efficacy endpoints including the proportion of patients diagnosed with proven or probable IFD were analysed using a nonstratum-adjusted relative risk reduction.</s><s>The time to diagnosis of proven or probable IFD and the duration of remission-induction chemotherapy were analysed using Kaplan-Meier estimates and the log rank test, after stratifying by region.</s><s>A P value of ,0.05 was considered statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>From April 2011 to November 2013, 391 patients were screened and 360 were enrolled.</s><s>Five patients were not treated and 16 failed to meet the entry criteria, i.e. 15 received protocol-prohibited systemic antifungal treatment in the 30 days prior to first dose of study drug and 1 did not have ALL.</s><s>Hence, 339 patients were included in the efficacy analysis.</s><s>The safety analysis comprised 355 patients who received at least one dose of study drug (Figure <ref type="figure" target="#fig_0">1</ref>), of whom 237 were randomly allocated to receive L-AMB and 118 to receive placebo.</s></p><p><s>Demographic and baseline characteristics were similar across the treatment groups (Table <ref type="table" target="#tab_0">1</ref>).</s><s>The median age was 46 (IQR 30-58) years.</s><s>Commonly used constituents of chemotherapy for remission induction included cytarabine, cyclophosphamide, vincristine and anthracyclines, particularly daunorubicin and idarubicin.</s><s>Systemic glucocorticosteroids were part of the chemotherapy in the majority of patients [L-AMB 90.4% (206/228), placebo 91.0% (101/111)].</s><s>Over 90% of subjects received twiceweekly infusions of study drug as specified in the protocol.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy analyses</head><p><s>Rates of proven/probable IFD as assessed by the IDRB (primary endpoint) were 7.9% (18/228) in the L-AMB and 11.7% (13/111) in the placebo group (P " 0.24), suggesting that L-AMB is not effective as prophylaxis against IFD in these patients.</s><s>The remission-induction phase was a median of 22 days for both groups.</s><s>Additionally, rates of possible IFD were 4.8% (11/228) in the L-AMB and 5.4% (6/111)  in the placebo group (P " 0.82) (Table <ref type="table" target="#tab_1">2</ref>, Table <ref type="table" target="#tab_1">S2</ref>).</s></p><p><s>The IFD incidence rates for patients who were neutropenic for 10 days (n " 258) were 6.9% in the L-AMB group versus 13.1% in the placebo group (P " 0.10) (Table <ref type="table" target="#tab_1">2</ref>; Table <ref type="table" target="#tab_2">S3</ref>).</s></p><p><s>Subgroup analyses of the primary endpoint showed that the proportion of patients with proven or probable IFD was consistently lower in the L-AMB group than in the placebo group (Figure <ref type="figure">S4</ref>).</s><s>Time to diagnosis of IFD was not significantly different between the two study groups (P " 0.33) (Figure <ref type="figure" target="#fig_1">2</ref>).</s></p><p><s>Chest CT scans were done for 82 (36.0%) patients in the L-AMB group and 51 (45.9%) patients in the placebo group.</s><s>Antifungal treatment was given during remission-induction chemotherapy to 16.2% (37/228) patients in the L-AMB group and 21.6% (24/111) in the placebo group (P " 0.22).</s><s>These treatments were considered protocol violations in eight patients in each group.</s></p><p><s>Overall mortality was similar between the groups, being 7.2% (17/237) in the L-AMB group and 6.8% (8/118) in the placebo group (P " 1.00) (Figure <ref type="figure">S5</ref>).</s><s>Two deaths in the L-AMB group were attributed to IFD by the IDRB (probable invasive pulmonary aspergillosis and proven candidaemia), but none in the placebo group.</s></p><p><s>Most patients in each group were neutropenic (,500/lL) during remission-induction chemotherapy (L-AMB 90.8%; placebo 92.8%), and 76.3% and 75.7% were neutropenic for 10 days.</s><s>Median duration of neutropenia ,500/lL was 18 days for both groups (IQR L-AMB 13.0-26.0,</s><s>placebo 11.0-25.0</s><s>days).</s><s>The absolute neutrophil count nadir was ,100/lL in 167 (73.2%) patients in the L-AMB group and 82 (73.9%) patients in the placebo group.</s></p><p><s>There was no significant difference in the median duration of neutropenia.</s></p><p><s>Complete remission rates were lower in the L-AMB group [72.8% (166/228)] than in the placebo group [79.3% (88/111)], although not significantly so (P " 0.20).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Antifungal prophylaxis in ALL induction</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>JAC</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Post hoc efficacy analysis on patients without major protocol deviations</head><p><s>For this analysis, a total of 44 patients in the L-AMB group and 21 in the placebo group were excluded from the ITT analysis set because of at least one protocol deviation that could have influenced the primary endpoint.</s><s>This included 41 patients who received systemic antifungals in violation of the protocol (24 L-AMB versus 17 placebo), 2 patients in the L-AMB group with baseline IFD and 28 patients who had not been given regimens expected to induce 10 days of neutropenia (21 L-AMB versus 7 placebo).</s><s>IFD rates in the remaining 274 patients were 7.6% (14/184) in the L-AMB group and 14.4% (13/90) in the placebo group (P " 0.07).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pharmacokinetic analyses</head><p><s>A total of 175 trough pharmacokinetic samples were collected from 27 patients given L-AMB between 1.4 and 6.4 days after the previous dose of study drug.</s><s>Mean + SD trough serum concentration of free amphotericin B ranged from 0.89+0.59 to 1.58+1.55</s><s>lg/mL.</s><s>Cornely et al.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety analyses</head><p><s>Of 355 patients treated, 61.7% (219/355) completed study drug treatment for the planned duration: L-AMB 59.9% (142/237) and placebo 65.3% (77/118) (P " 0.36) (Table <ref type="table" target="#tab_2">3</ref>).</s><s>Patients in both treatment groups remained on study drug for a median 22 days (IQR L-AMB 15-32, placebo 15-36 days).</s><s>The reasons for premature  Antifungal prophylaxis in ALL induction JAC discontinuation of study drug were similar in the two groups, most commonly because of an AE, the investigator's discretion or withdrawal of consent.</s><s>Most patients had at least one AE and a similar proportion of patients in each group had AEs of grade 3 or higher. <ref type="bibr" target="#b93">16,</ref><ref type="bibr" target="#b97">20</ref></s><s>Most patients in each group had AEs considered by the investigator to be related to ALL or to chemotherapy.</s><s>A similar proportion of patients in each group had AEs considered to be related to IFD or AEs that resulted in premature discontinuation of the study drug.</s><s>More patients in the L-AMB group had an AE that resulted in interruption of treatment with the study drug (20.3% versus 7.6%; P " 0.002), and experienced serious AEs (Table <ref type="table">S4</ref>) considered related to study drug by the investigator (8.4% versus 1.7%; P " 0.02).</s><s>Statistically significantly more patients were affected by hypokalaemia and elevated creatinine in the L-AMB group (Table <ref type="table" target="#tab_2">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This large, randomized, double-blind, placebo-controlled study, using a pre-specified diagnostic algorithm, showed that almost 1 in 11 patients receiving remission-induction chemotherapy for ALL developed a probable or proven IFD.</s><s>This is almost twice the rate reported in a retrospective cohort study 2 and is of the same order of magnitude as reported for patients receiving remissioninduction therapy for AML without mould-directed antifungal prophylaxis. <ref type="bibr" target="#b86">10</ref></s><s>The observed incidence in this study is also towards the upper end of IFD rates reported in other retrospective case collections in patients with ALL of between 6.5% and 8.8%. <ref type="bibr" target="#b78">2,</ref><ref type="bibr" target="#b83">7,</ref><ref type="bibr" target="#b84">8</ref></s><s>It is therefore important to consider the potential factors behind this possibly high observed incidence, which resulted from a prospective trial with a well-designed diagnostic algorithm.</s></p><p><s>Neutropenia and prolonged treatment with glucocorticosteroids are considered host factors that may contribute to the high incidence of IFD observed. <ref type="bibr" target="#b80">4</ref></s><s>Another factor may be the inclusion of non-culture-based methods in our diagnostic strategy, which may have led to a higher number of cases of IFD being identified.</s><s>In any event, the high incidence observed clearly warrants further investigation and consideration of appropriate preventative measures, including antifungal prophylaxis.</s></p><p><s>2]<ref type="bibr" target="#b90">[13]</ref> The dose used was chosen to minimize toxicity but may not have been high enough to be effective, representing a major limitation of the study.</s><s>However, despite the low dose (half the standard treatment dose of 3 mg/kg/day), the number of withdrawals due to AEs and the number of serious AEs were both much higher with L-AMB than with placebo.</s><s>The dosing interval was chosen on practical grounds and may have been too long, although pharmacokinetic analysis showed that L-AMB trough concentrations were Treatment emergent is defined as started on or after first dose and up to 30 days after last dose of study drug.</s></p><p><s>Cornely et al.</s></p><p><s>adequate. <ref type="bibr" target="#b103">26,</ref><ref type="bibr" target="#b104">27</ref></s><s>Better understanding of the pharmacokinetics of L-AMB is therefore necessary to identify the most appropriate dosage for prophylaxis.</s></p><p><s>Other factors to consider include the point that the 10% estimate of the IFD rate for the placebo group was exceeded, but expecting a 75% reduction in IFD incidence in the sample size calculation may have been too optimistic. <ref type="bibr" target="#b86">10,</ref><ref type="bibr" target="#b101">24,</ref><ref type="bibr" target="#b102">25</ref></s><s>Attrition of statistical power due to protocol deviations may provide a further explanation.</s></p><p><s>Some patients were included although they received regimens that did not induce severe neutropenia, and others received systemic antifungal agents in violation of the protocol despite detailed management algorithms for suspected IFD that may have impacted the assessment of the primary endpoint.</s><s>This early antifungal treatment may have caused false negativity of the diagnostic-driven strategy applied.</s><s>Post hoc analyses of the group of patients without substantial protocol deviations showed that the difference between treatment groups was more pronounced, though this did not reach statistical significance.</s><s>The lack of neutropenia in subjects was not explained by the use of growth factors.</s></p><p><s>Complete remission rates were lower than expected, but this is likely to be due to evaluation of subjects before the end of induction/beginning of consolidation and to some subjects being lost to follow-up (Figure <ref type="figure" target="#fig_0">1</ref>).</s></p><p><s>Mortality was very similar in both treatment groups (7.2% versus 6.8%), and deaths in the placebo group were not attributed to IFD by the investigators.</s><s>The diagnostic-driven strategy may pick up IFD earlier at a more effectively treatable stage.</s><s>Because the trial did not reveal a difference in overall mortality or in mortality attributable to IFD, a diagnostic-driven treatment approach may be a more suitable strategy in this specific patient population.</s><s>While prophylaxis is beneficial for patients receiving remissioninduction chemotherapy for AML, 10 heightened clinical awareness combined with intensive microbiological screening may be appropriate for those undergoing similar treatment for ALL.</s></p><p><s>L-AMB was not effective in preventing IFD in patients receiving remission-induction chemotherapy for ALL.</s><s>Tolerability of L-AMB was what might be expected but further studies are clearly needed to determine whether a change in dosing might have yielded better results.</s><s>Nonetheless, the rate of IFD found in this study was higher than that reported in previous studies; however, whether prophylaxis is the best antifungal strategy during remissioninduction chemotherapy of ALL, or whether the use of a diagnostic-driven approach combining intensive clinical and microbiological screening to detect IFD at an early stage would be more appropriate, remains to be seen.</s><s>Finally, even though L-AMB given as prophylaxis did not prove effective in our study, this should not deter others from exploring this subject further, given the high incidence of IFD in this patient population.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure1.</s><s>CONSORT flow diagram.</s><s>Of 360 subjects randomized, 5 were never dosed, and 16 (9 L-AMB, 7 placebo) were excluded from the efficacy analysis, 1 due to misdiagnosis (AML) and 15 due to protocol-prohibited antifungal treatment either concomitant with or within the previous 30 days.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Time to diagnosis of invasive fungal disease as assessed by the independent data review board.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Patient baseline characteristics</s></p></div></figDesc><table><row><cell>Characteristic</cell></row></table><note><p><s>a Cochran-Mantel-Haenszel test for categorical variables and Wilcoxon rank-sum test for continuous variables.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Invasive fungal disease rates AMB, two placebo) had Pneumocystis spp. in bronchoalveolar lavage (BAL) and were not considered to have IFD as it is not part of the EORTC/MSG criteria.Major protocol deviations were protocol-prohibited systemic antifungals, baseline IFD or chemotherapy not expected to induce sufficient neutropenia.</s></p></div></figDesc><table><row><cell>Patient population</cell></row></table><note><p><s>a Stratum-adjusted (stratified by region) CMH test.b C. kefyr.c</s><s>C. albicans (2%), C. tropicalis bloodstream infections.d</s><s>Probable invasive pulmonary aspergillosis, proven candidaemia.e</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 .</head><label>3</label><figDesc><div><p><s><ref type="bibr" target="#b98">21</ref>verse events as assessed by the investigators21</s></p></div></figDesc><table><row><cell>Adverse events, n (%)</cell><cell>L-AMB (N " 237)</cell><cell>Placebo (N " 118)</cell><cell>P value a</cell></row><row><cell>Any treatment-emergent b AE</cell><cell>237 (100)</cell><cell>115 (97.5)</cell><cell>0.036</cell></row><row><cell>pyrexia</cell><cell>67 (28.3)</cell><cell>40 (33.9)</cell><cell>0.33</cell></row><row><cell>hypotension</cell><cell>18 (7.6)</cell><cell>15 (12.7)</cell><cell>0.12</cell></row><row><cell>Treatment-emergent b renal AEs</cell><cell></cell><cell></cell><cell></cell></row><row><cell>hypokalaemia, any grade</cell><cell>83 (35.0)</cell><cell>21 (17.8)</cell><cell>,0.001</cell></row><row><cell>,LLN (3.0 mmol/L)</cell><cell>45 (19.0)</cell><cell>12 (10.2)</cell><cell>0.03</cell></row><row><cell>,LLN (3.0 mmol/L); symptomatic, intervention indicated</cell><cell>25 (10.5)</cell><cell>6 (5.1)</cell><cell>0.11</cell></row><row><cell>,3.0-2.5 mmol/L</cell><cell>10 (4.2)</cell><cell>2 (1.7)</cell><cell>0.35</cell></row><row><cell>,2.5 mmol/L</cell><cell>3 (1.3)</cell><cell>1 (0.8)</cell><cell>1.00</cell></row><row><cell>creatinine increase, any grade</cell><cell>22 (9.3)</cell><cell>0</cell><cell>,0.001</cell></row><row><cell>.1 to 1.5% baseline; .ULN to 1.5 % ULN</cell><cell>7 (3.0)</cell><cell>0</cell><cell>0.10</cell></row><row><cell>.1.5 to 3.0% baseline; .1.5 to 3.0 % ULN</cell><cell>15 (6.3)</cell><cell>0</cell><cell>0.003</cell></row><row><cell>.3.0% baseline; .3.0 to 6.0 % ULN</cell><cell>0</cell><cell>0</cell><cell>1.00</cell></row><row><cell>Other AE categories</cell><cell></cell><cell></cell><cell></cell></row><row><cell>serious adverse events (SAEs)</cell><cell>79 (33.3)</cell><cell>38 (32.2)</cell><cell>0.90</cell></row><row><cell>SAE related to study drug, any grade</cell><cell>20 (8.4)</cell><cell>2 (1.7)</cell><cell>0.02</cell></row><row><cell>AE leading to study drug interruption</cell><cell>48 (20.3)</cell><cell>9 (7.6)</cell><cell>0.002</cell></row><row><cell>AE leading to study drug discontinuation</cell><cell>63 (26.6)</cell><cell>26 (22.0)</cell><cell>0.37</cell></row><row><cell>any grade 3 AE</cell><cell>102 (43.0)</cell><cell>43 (36.4)</cell><cell>0.25</cell></row><row><cell>any grade 4 AE</cell><cell>69 (29.1)</cell><cell>40 (33.9)</cell><cell>0.39</cell></row><row><cell>AE related to death</cell><cell>17 (7.2)</cell><cell>8 (6.8)</cell><cell>1.00</cell></row><row><cell>AE related to ALL or ALL treatments</cell><cell>226 (95.4)</cell><cell>110 (93.2)</cell><cell>0.45</cell></row><row><cell>AE related to IFD</cell><cell>17 (7.2)</cell><cell>10 (8.5)</cell><cell>0.67</cell></row><row><cell>LLN, lower limit of normal; ULN, upper limit of normal.</cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>a Fisher's exact test.</s><s>b</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We extend our thanks to the participating patients, the investigators and their support staff.</s><s>We also acknowledge the contribution of the Data Safety Monitoring Board (DSMB; A. Pagliuca, A. J. Ullmann, C. Viscoli and D. Wang), and the continuous reliable support of S. Abella MD, R. Hargreaves, E. Harvey, S. Sanchez and C. Simcock.</s><s>6-9 December 2014, San Francisco, CA, USA (Blood 2014; 24: 3646).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Members of the AmBiGuard Study Group</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Transparency declarations</head><p><s>Note: The use of liposomal amphotericin B (AmBisomeV R ) in this study is off-label.</s></p><p><s>O. A. C. reports research grants from Actelion, Aramis Pharma, Astellas, AstraZeneca, Basilea, Bayer, Cidara, Duke University (NIH UM1AI104681), F2G, Gilead, GSK, Leeds University, MedPace, Melinta Therapeutics, Merck/MSD, Miltenyi, Pfizer, Rempex, Roche, Sanofi Pasteur, Scynexis, Seres Therapeutics, The Medicine Company, is a consultant to Achaogen, Anacor, Amplyx, Actelion, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen Pharmaceuticals, Matinas, Menarini Ricerche, Merck/MSD, Paratek Pharmaceuticals, Scynexis, Seres, Summit, Tetraphase, Vical, Vifor, and received lecture honoraria from Astellas, Basilea, Gilead and Merck/MSD, outside the submitted work.</s><s>T. L. has no conflicts of interest to disclose.</s><s>J. M. reports grants, personal fees and non-financial support from Gilead Sciences, MSD and Pfizer, and personal fees and non-financial support from Astellas.</s><s>M. J. G. T. V. has served at the speakers' bureau of Pfizer, Merck, Gilead Sciences, and Astellas Pharma, received research funding from 3 M, Astellas Pharma and Gilead Sciences and is a consultant to Berlin Chemie.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary data</head><p><s>Tables S1 to S4 and Figures S1 to S5 are available as Supplementary data at JAC Online.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>This study was funded by Gilead Sciences, Inc. M. B., W. G. and M. J. H. are employees of Gilead Sciences.</s><s>All other authors or their institutions have received compensation for study participation from Gilead Sciences International Ltd.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">:</forename><forename type="middle">G</forename><surname>Argentina</surname></persName>
		</author>
		<author>
			<persName><surname>Jarchum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">patient</title>
		<imprint>
			<date>1</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Instituto</forename><forename type="middle">Alexander</forename><surname>Dictar</surname></persName>
		</author>
		<author>
			<persName><surname>Fleming</surname></persName>
		</author>
		<imprint>
			<pubPlace>Buenos Aires</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Hospital Italiano de La Plata</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Ramirez</forename><surname>Borga</surname></persName>
		</author>
		<imprint>
			<pubPlace>La Plata</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<author>
			<persName><forename type="first">A</forename><surname>Valledor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Austria: P. Knoebl</title>
				<meeting><address><addrLine>Buenos Aires</addrLine></address></meeting>
		<imprint/>
		<respStmt>
			<orgName>Medizinische Univ</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Wien</forename><surname>Wien</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Paracelsus Medical Univ. Salzburg</title>
		<imprint>
			<biblScope unit="issue">3</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">W</forename><surname>Linkesch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sill</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medizinische Univ</title>
		<editor>B. De Prijck, CHU Sart-Tilman</editor>
		<imprint>
			<biblScope unit="issue">4</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Sonet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CH Mont-Godinne</title>
		<imprint>
			<biblScope unit="issue">4</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Jessa</forename><surname>Theunissen</surname></persName>
		</author>
		<author>
			<persName><surname>Ziekenhuis</surname></persName>
		</author>
		<imprint>
			<pubPlace>Hasselt</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">D</forename><surname>Selleslag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Sint-Jan Brugge-Oostende</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Brugge</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Maertens</surname></persName>
		</author>
		<author>
			<persName><surname>Leuven</surname></persName>
		</author>
		<imprint>
			<pubPlace>Leuven</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L M</forename><surname>Nucci</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hospital Univ. Clementino Fraga Filho</title>
		<imprint>
			<biblScope unit="issue">2</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Lopes De Castro Lobo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rio</forename><surname>Hemorio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Janeiro</forename><surname>De</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title/>
		<author>
			<persName><surname>Fogliatto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Vandoeuvre les Nancy</title>
		<editor>C. Bonmati</editor>
		<imprint>
			<biblScope unit="issue">7</biblScope>
		</imprint>
		<respStmt>
			<orgName>Hospital de Cl ınicas de Porto Alegre ; CHU de Nancy, Ho ˆpitaux de Brabois</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">P</forename><surname>Turlure</surname></persName>
		</author>
		<imprint>
			<pubPlace>Limoges</pubPlace>
		</imprint>
		<respStmt>
			<orgName>CHU de Limoges</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename><surname>Herbrecht</surname></persName>
		</author>
		<author>
			<persName><surname>Ho ˆpital De Hautepierre</surname></persName>
		</author>
		<imprint>
			<pubPlace>Strasbourg</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Thiebaut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Grenoble</forename><surname>Ho ˆpital A. Michallon</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Michallet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Centre</forename><surname>Hospitalier Lyon</surname></persName>
		</author>
		<author>
			<persName><surname>Sud</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">T</forename><surname>Leguay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Germany: G. Egerer, Univ. Hospital Heidelberg</title>
		<imprint>
			<biblScope unit="issue">31</biblScope>
		</imprint>
		<respStmt>
			<orgName>CHU Bordeaux Haut Leveque</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">G</forename><surname>Silling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Univ. Hospital Mu ¨nster, Mu ¨nster</title>
		<imprint>
			<biblScope unit="issue">1</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Pfreundschuh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Univ</forename><surname>Saarland</surname></persName>
		</author>
		<imprint>
			<pubPlace>Homburg/Saar</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Universit€ atsmedizin Go ¨ttingen</title>
		<author>
			<persName><surname>Hasenkamp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Go ¨ttingen</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Kraemer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Klinikum Oldenburg GmbH</title>
		<imprint>
			<biblScope unit="issue">2</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Topp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Heinz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Univ</forename><surname>Wu ¨rzburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wu</forename><surname>¨rzburg</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Junghanss</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Univ. Hospital Rostock</title>
		<imprint>
			<biblScope unit="issue">2</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Schaich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Parmentier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Roellig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Univ</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hospital Carl Gustav Carus</title>
		<imprint>
			<biblScope unit="issue">3</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Beck</surname></persName>
		</author>
		<imprint>
			<pubPlace>Mainz</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Universit€ atsmedizin der Johannes Gutenberg-Universit€ at Mainz</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Hu ¨ttmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Univ. Hospital Essen</title>
		<imprint>
			<biblScope unit="issue">4</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Mousset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">N</forename><surname>Duenzinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Univ. Hospital Frankfurt, Frankfurt am Main</title>
		<imprint>
			<biblScope unit="issue">4</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Schwartz</surname></persName>
		</author>
		<imprint>
			<pubPlace>Berlin</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Charite Universitaetsmedizin Berlin</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">G</forename><surname>Haerter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Comprehensive Infectious Diseases Center (CIDC)</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Kondakci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Univ</forename></persName>
		</author>
		<imprint/>
	</monogr>
	<note>Hospital Du ¨sseldorf, Du ¨sseldorf</note>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<monogr>
		<author>
			<persName><forename type="first">C</forename><surname>Ostermann</surname></persName>
		</author>
		<author>
			<persName><surname>Rieger</surname></persName>
		</author>
		<title level="m">Klinikum der Universit€ at Mu ¨nchen, Mu ¨nchen</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Cornely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J G T</forename><surname>Vehreschild</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Univ. Hospital Ko ¨ln, Ko ¨ln</title>
		<imprint>
			<biblScope unit="issue">18</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">:</forename><forename type="middle">P</forename><surname>Greece</surname></persName>
		</author>
		<author>
			<persName><surname>Tsirigotis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">General Univ. Hospital Attikon</title>
		<imprint>
			<biblScope unit="issue">1</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">P</forename><surname>Matsouka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Univ. General Hospital of Larissa</title>
		<imprint>
			<biblScope unit="issue">3</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Angelopoulou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Laiko General Hospital of Athens</title>
		<imprint>
			<biblScope unit="issue">4</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Karakantza</surname></persName>
		</author>
		<author>
			<persName><surname>Spyridonidis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">General Univ. Hospital of Patras</title>
		<imprint>
			<biblScope unit="issue">7</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Israel: A. Kolomansky</title>
		<author>
			<persName><forename type="first">A</forename><surname>Anagnostopoulos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">General Hospital of Thessaloniki G. Papanikolaou</title>
		<imprint>
			<biblScope unit="issue">12</biblScope>
		</imprint>
	</monogr>
	<note>Tel Aviv Medical Center, Tel Aviv</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Moses</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hadassah Medical Center</title>
		<imprint>
			<biblScope unit="issue">1</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">N</forename><surname>Horowitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rambam Health Care Campus</title>
		<imprint>
			<biblScope unit="issue">3</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">G</forename><surname>Rahav</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Chaim</forename><surname>Sheba Medical</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ramat</forename><surname>Center</surname></persName>
		</author>
		<author>
			<persName><surname>Gan</surname></persName>
		</author>
		<editor>F. Aversa, A. Velardi, Ospedale Santa Maria della Misericordia</editor>
		<imprint>
			<pubPlace>Perugia</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Pagano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Policlinico Universitario Agostino</forename><surname>Gemelli</surname></persName>
		</author>
		<imprint>
			<pubPlace>Rome</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">G</forename><surname>Gentile</surname></persName>
		</author>
		<imprint>
			<pubPlace>Rome</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Universit a La Sapienza di Roma</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Gobbi</surname></persName>
		</author>
		<imprint>
			<publisher>AOU) S. Martino</publisher>
			<pubPlace>Genova</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Universit a degli studi di Genova-Azienda Ospedaliero-Universitaria</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>Luppi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Nosari</surname></persName>
		</author>
		<imprint>
			<pubPlace>Modena</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Ospedaliero-Universitaria Policlinico di Modena</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Rambaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ospedali Riuniti Di</forename><surname>Bergamo</surname></persName>
		</author>
		<imprint>
			<pubPlace>Bergamo</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">A</forename><surname>Candoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Santa</forename><forename type="middle">Maria</forename><surname>Della Misericordia</surname></persName>
		</author>
		<imprint>
			<pubPlace>Udine</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Marbello</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ospedale Niguarda</title>
		<imprint>
			<biblScope unit="issue">4</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">G</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Spedali</forename><surname>Civili Di Brescia</surname></persName>
		</author>
		<imprint>
			<pubPlace>Brescia</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">E</forename><surname>Pogliani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Verga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ospedale</forename><surname>San</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gerardo</forename></persName>
		</author>
		<imprint>
			<pubPlace>Monza</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">B</forename><surname>Allione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Giovanni</forename><surname>Aou San</surname></persName>
		</author>
		<author>
			<persName><surname>Battista Di Torino</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<monogr>
		<title level="m" type="main">Portugal: I. Moreira, Instituto Português de Oncologia do</title>
		<author>
			<persName><forename type="first">C</forename><surname>Castagnola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Irccs</forename><surname>Fondazione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Matteo</forename><surname>Policlinico San</surname></persName>
		</author>
		<imprint>
			<pubPlace>Pavia; Porto, EPE, Porto</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<author>
			<persName><forename type="first">A</forename><surname>Nunes</surname></persName>
		</author>
		<title level="m">Instituto Portugues de Oncologia (IPO)</title>
				<meeting><address><addrLine>Lisboa</addrLine></address></meeting>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Hospital Santo Ant onio dos Capuchos</title>
		<author>
			<persName><forename type="first">A</forename><surname>Botelho De</surname></persName>
		</author>
		<author>
			<persName><surname>Sousa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CHLC</title>
		<imprint>
			<biblScope unit="issue">7</biblScope>
		</imprint>
		<respStmt>
			<orgName>Hospital Universitario Virgen de la Arrixaca</orgName>
		</respStmt>
	</monogr>
	<note>Spain: A. I. Rubio Tejero</note>
</biblStruct>

<biblStruct xml:id="b59">
	<monogr>
		<title level="m" type="main">Hospital Universitario Central de Antifungal prophylaxis in ALL induction JAC</title>
		<author>
			<persName><forename type="first">C</forename><surname>Vallejo</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Asturias (HUCA)</title>
		<imprint>
			<biblScope unit="issue">1</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">L</forename><surname>Vazquez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hospital Universitario de Salamanca</title>
		<imprint>
			<biblScope unit="issue">1</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Hospital Universitari Son Espases</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Besalduch</forename><surname>Vidal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Palma de Mallorca</title>
		<imprint>
			<biblScope unit="issue">1</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">V</forename><surname>Gomez-Garcia De Soria</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">HULP)</title>
		<imprint>
			<biblScope unit="issue">1</biblScope>
		</imprint>
		<respStmt>
			<orgName>Hospital Universitario de La Princesa</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Jurado</forename><surname>Chacon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hospital</title>
		<imprint>
			<biblScope unit="issue">1</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Gonz</surname></persName>
		</author>
		<author>
			<persName><surname>Campos</surname></persName>
		</author>
		<imprint>
			<pubPlace>Sevilla</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Hospital Universitario Virgen del Roc ıo</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">E</forename><surname>Olavarria</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Complejo Hospitalario de Navarra</title>
		<imprint>
			<biblScope unit="issue">3</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<monogr>
		<author>
			<persName><forename type="first">P</forename><surname>Barba</surname></persName>
		</author>
		<title level="m">Hospital Vall d&apos;Hebron</title>
				<meeting><address><addrLine>Barcelona</addrLine></address></meeting>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>De La Serna Torroba</surname></persName>
		</author>
		<imprint>
			<pubPlace>Madrid</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Hospital Universitario 12 de Octubre</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Duran</forename><surname>Duarte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Reynals Hospital</title>
		<editor>Switzerland: D. Heim</editor>
		<imprint>
			<biblScope unit="issue">8</biblScope>
		</imprint>
		<respStmt>
			<orgName>Universit€ atsspital Basel</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">S</forename><surname>Zimmerli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Univ. Hospital Inselspital</title>
		<imprint>
			<biblScope unit="issue">2</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">B</forename><surname>Gerber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Liv Hospital</title>
		<editor>M. Akova</editor>
		<imprint>
			<biblScope unit="issue">4</biblScope>
		</imprint>
		<respStmt>
			<orgName>Universit€ atsspital Zurich</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Z</forename><surname>Bolaman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">School of Medicine</title>
		<imprint>
			<biblScope unit="issue">1</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">F</forename><surname>Tabak</surname></persName>
		</author>
		<imprint>
			<pubPlace>Istanbul</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Istanbul University Hospital</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<monogr>
		<author>
			<persName><forename type="first">H</forename><surname>Akan</surname></persName>
		</author>
		<title level="m">Cebeci Hospital, Cebeci</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">E</forename><surname>Senol</surname></persName>
		</author>
		<imprint>
			<pubPlace>Besevler</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Gazi University Hospital</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Modern therapy of acute lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">R</forename><surname>Bassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hoelzer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="532" to="543" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Pagano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Caira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Candoni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="1068" to="1075" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Epidemiology of invasive fungal disease in lymphoproliferative disorders</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Teng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Slavin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">W</forename><surname>Teh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="e462" to="466" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ MSG) Consensus Group</title>
		<author>
			<persName><forename type="first">B</forename><surname>De Pauw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Donnelly</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1813" to="1821" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Patients at high risk of invasive fungal infections: when and how to treat</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ru ¨ping</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Vehreschild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Cornely</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1941" to="1962" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Doan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Kirkpatrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Walker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="497" to="505" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Invasive fungal diseases in patients with acute lymphoid leukemia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nicolato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Noue ´r</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Garnica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="2014" to="2019" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Mariette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tavernier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hocquet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="586" to="593" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology</title>
		<author>
			<persName><forename type="first">D</forename><surname>Tacke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Buchheidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Karthaus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Hematol</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="1449" to="1456" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Cornely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Maertens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Winston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">356</biblScope>
			<biblScope unit="page" from="348" to="359" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Kuse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Chetchotisakd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Da Cunha</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="1519" to="1527" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<monogr>
		<title/>
		<author>
			<persName><surname>Cornely</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a highloading dose regimen with standard dosing (AmBiLoad trial)</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Cornely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Maertens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bresnik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1289" to="1297" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Cornely</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arikan-Akdagli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Dannaoui</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="5" to="26" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience</title>
		<author>
			<persName><forename type="first">J</forename><surname>Adler-Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Proffitt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="21" to="30" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans</title>
		<author>
			<persName><forename type="first">I</forename><surname>Bekersky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Fielding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Dressler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="828" to="833" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Yeldandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mcevoy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="2391" to="2398" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial</title>
		<author>
			<persName><forename type="first">O</forename><surname>Penack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1306" to="1312" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Cordonnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mohty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Faucher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="135" to="141" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Mattiuzzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Estey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Raad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="450" to="456" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Kelsey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Goldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mccann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="163" to="168" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tollemar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Ringden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Andersson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bone Marrow Transplant</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="577" to="582" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<monogr>
		<title level="m" type="main">Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03</title>
		<imprint>
			<date type="published" when="2010">2010</date>
			<publisher>NIH Publication</publisher>
			<biblScope unit="page" from="9" to="5410" />
			<pubPlace>USA</pubPlace>
		</imprint>
		<respStmt>
			<orgName>National Cancer Institute</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Diagnosis of invasive fungal infections in hematology and oncology-guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ruhnke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bo ¨hme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Buchheidt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="823" to="833" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Winston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Greenfield</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">326</biblScope>
			<biblScope unit="page" from="845" to="851" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Slavin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Osborne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Adams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">171</biblScope>
			<biblScope unit="page" from="1545" to="1552" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients</title>
		<author>
			<persName><forename type="first">G</forename><surname>Wu ¨rthwein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lanvers-Kaminsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="536" to="543" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<monogr>
		<title level="m" type="main">Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method</title>
		<author>
			<persName><forename type="first">A</forename><surname>Espinel-Ingroff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cuenca-Estrella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fothergill</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>M38-A2 document</note>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="5150" to="5154" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
